Clinical Scenario: A PD-L1-Low Patient with NSCLC

Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.

Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.

The therapeutic cancer vaccine OSE2101 combined with either docetaxel or nivolumab met the primary end point of 1-year overall survival in the Combi-TED trial.

The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.